Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05364502 · ClinicalTrials.gov registry record · NA
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
A NA study of Arterial Bleeding in Solid Organs and Peripheral Arteries, sponsored by Instylla.
- Active
- Registry status
- NA
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT05364502: Active NA study of Arterial Bleeding in Solid Organs and Peripheral Arteries, sponsored by Instylla.
NCT05364502 is a NA study of Arterial Bleeding in Solid Organs and Peripheral Arteries that is active but no longer recruiting, run by Instylla. The registered enrollment target is 130 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05364502, a NA study of Arterial Bleeding in Solid Organs and Peripheral Arteries, is active but no longer recruiting, sponsored by Instylla.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.
Primary Outcome
Freedom from major adverse events (MAE)
Conditions Studied
Interventions
- DEVICE Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter
Study Locations (20)
California
- Memorial Health Services - Long Beach
- Stanford University - Stanford
- UCLA Harbor Lindquist Institute - Torrance
Connecticut
- Nuvance Health - Danbury
- Yale University - New Haven
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Medical Center - Boston
New York
- Mount Sinai Hospital - New York
- Columbia University Milstein - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh - Pittsburgh
Arizona
- Banner Health - Phoenix
District of Columbia
- Medstar Georgetown University - Washington D.C.
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2026-03 |
| Phase | NA |
What the registry record for NCT05364502 still lists
NCT05364502 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Arterial Bleeding in Solid Organs and Peripheral Arteries appearing as the primary indexed condition, and to 1 intervention - of which Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter is the first listed.
NCT05364502 names 20 study sites across 14 states, led by California, Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05364502 about?
NCT05364502 is a clinical study titled "(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds". To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.
What is the current status of trial NCT05364502?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2022-12-12. Estimated completion is 2026-03.
What conditions does trial NCT05364502 study?
This clinical trial studies the following conditions: Arterial Bleeding in Solid Organs and Peripheral Arteries.
What interventions are being tested in trial NCT05364502?
The interventions under investigation include: Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter (DEVICE).
Who is sponsoring clinical trial NCT05364502?
This trial is sponsored by Instylla, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05364502 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05364502's enrollment target sits among peer trials
130 733rd of 2000 higher than 1,257 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI